✅ Model Answer: • Skin condition: Linear scleroderma (a subtype of localized scleroderma).
• Most common complication affecting lower limb: Growth failure leading to limb-length discrepancy (shortening of the affected limb).
• Other features: Muscle wasting, joint contractures, subcutaneous tissue loss, and skin atrophy/hypopigmentation.

✅ Model Answer: • Pathophysiology: Linear scleroderma can involve deep tissues beyond the dermis, including subcutaneous fat, muscle, fascia, and bone.
• Chronic inflammation and fibrosis in these deep tissues impair normal growth of the limb.
• Bone involvement: Inflammatory changes in the periosteum and bone can lead to growth retardation (epiphyseal plate involvement).
• Ischemia: Vascular compromise from fibrosis contributes to reduced tissue perfusion and growth failure.
• The result is a shorter, atrophic limb with muscle wasting and joint contractures.

✅ Model Answer: • Clinical features:
- Linear, indurated band of skin (often on an extremity, scalp/forehead, or trunk).
- Hypopigmentation (sometimes hyperpigmentation) and skin atrophy.
- "En coup de sabre" – linear lesion on the forehead/scalp.
- Deep tissue involvement: Subcutaneous fat loss, muscle wasting, and joint contractures.
- Limb shortening (growth failure) – a key complication when the lesion crosses a joint or affects the bone.
- Joint contractures – especially when the lesion crosses a joint (e.g., knee, ankle).
- Pain – may be present but often asymptomatic.

✅ Model Answer: • Linear scleroderma (localized):
- Skin involvement is localized to a single area (linear band).
- No internal organ involvement (lungs, kidneys, heart, GI tract are spared).
- Raynaud phenomenon is typically absent.
- Acanthosis: Limited to skin and subcutaneous tissues (may involve muscle/bone locally).
- Treatment: Methotrexate ± corticosteroids.
- Prognosis: Good with early treatment; may cause cosmetic and functional issues.
• Systemic sclerosis:
- Diffuse skin thickening (sclerodactyly, face, trunk).
- Internal organ involvement (lung fibrosis, pulmonary hypertension, renal crisis, GI dysmotility).
- Raynaud phenomenon is universal.
- Treatment: Immunosuppression, vasodilators, supportive care.
- Prognosis: More severe, with significant morbidity and mortality.

✅ Model Answer: • Imaging studies:
- MRI (with contrast): Best modality to assess the extent of deep tissue involvement (subcutaneous fat, muscle, fascia, and bone marrow edema). Shows inflammation and fibrosis.
- X-ray (scanogram): Used to measure leg length discrepancy (standing X-ray from hips to ankles).
- Ultrasound: Can detect skin thickening and subcutaneous tissue involvement; useful for monitoring disease activity.
- CT scan: Less commonly used, but can show bone involvement.
- Dual-energy X-ray absorptiometry (DEXA): May be used to assess bone density if there is chronic disuse.

✅ Model Answer: • Methotrexate (MTX) role:
- First-line systemic therapy for active linear scleroderma (especially with deep tissue involvement).
- Mechanism: Antifolate and anti-inflammatory agent; reduces T-cell proliferation and cytokine production.
- Dose: 1 mg/kg/week (max 25 mg) subcutaneous or oral.
- Duration: Typically continued for 12-24 months until disease is inactive, then tapered.
- Often combined with: Corticosteroids (pulse or oral) for initial rapid disease control.
- Monitoring: CBC, liver function tests, renal function every 4-8 weeks.
- Benefits: Reduces disease activity, halts progression, and may improve skin and deep tissue involvement.

✅ Model Answer: • Corticosteroids role:
- Used as adjunctive therapy for active, progressive disease.
- Pulse methylprednisolone: 30 mg/kg/day IV (max 1 g) for 3 days, often given monthly for 3-6 months.
- Oral prednisone: 1-2 mg/kg/day (max 60 mg) for 4-6 weeks, then tapered.
- Indications: Rapidly progressing skin or deep tissue involvement, joint contractures, or significant growth failure.
- Combination: Usually used in combination with methotrexate to achieve rapid disease control.
- Side effects: Weight gain, Cushingoid features, immunosuppression, growth suppression (monitor carefully).

✅ Model Answer: • Physical therapy role:
- Prevention of joint contractures: Passive and active range-of-motion exercises.
- Stretching: To maintain flexibility and prevent muscle shortening.
- Strengthening exercises: To prevent muscle atrophy and improve function.
- Splinting: May be used to prevent contractures, especially if there is significant joint involvement.
- Gait training: If there is a leg length discrepancy or limp.
- Patient/family education: Home exercise programs to maintain joint mobility.

✅ Model Answer: • Measurement:
- Clinical measurement: Measure from the anterior superior iliac spine (ASIS) to the medial malleolus (true leg length).
- Scanogram (X-ray): Standing X-ray of both lower extremities from hips to ankles – the gold standard for accurate leg length measurement.
• Management:
- Shoe lift (shoe lift): For discrepancy of 1-2 cm – added to the shoe of the shorter leg.
- Epiphysiodesis: For significant discrepancy (>2-3 cm) – surgical procedure to arrest growth of the longer leg (performed when near skeletal maturity).
- Limb lengthening procedures: For severe discrepancies (>5 cm) – distraction osteogenesis.
- Orthopedic referral: For significant or progressive discrepancies.

✅ Model Answer: • Long-term complications:
- Limb-length discrepancy: Growth failure leads to shortening of the affected limb.
- Joint contractures: Especially at the knee or ankle, causing gait abnormalities.
- Muscle atrophy: Due to disuse and direct involvement.
- Functional impairment: Difficulty walking, running, or performing daily activities.
- Pain: Can be chronic due to contractures or muscle weakness.
- Cosmetic deformity: Skin changes and limb asymmetry.
- Secondary osteoarthritis: Due to abnormal joint mechanics.
- Psychosocial impact: Body image issues, social isolation.

✅ Model Answer: • En coup de sabre: A subtype of linear scleroderma affecting the scalp and forehead.
- Appearance: A linear, depressed, sclerotic band resembling a sword cut (coup de sabre – "sword stroke" in French).
- Associated features: Can extend to the underlying bone (frontal bone), leading to facial asymmetry and skull defects.
- Eye involvement: Can cause eyelid retraction, strabismus, or uveitis.
- Neurologic involvement: Seizures or focal neurologic deficits (if underlying brain involvement).
- Treatment: Similar to linear scleroderma – methotrexate ± corticosteroids.

✅ Model Answer: • MRI role:
- Assess deep tissue involvement: Shows the extent of inflammation and fibrosis in subcutaneous fat, muscle, fascia, and bone marrow.
- Detect active disease: T2-weighted imaging (STIR) shows increased signal (edema) in active lesions.
- Guide biopsy: Can identify the most active areas for biopsy.
- Monitor response to treatment: Decreased edema and inflammation on follow-up MRI indicates response to therapy.
- Identify complications: Muscle atrophy, joint contractures, bone involvement.
- Frequency: Often performed at diagnosis and then as clinically indicated.

✅ Model Answer: • "Your child has linear scleroderma, a condition that causes hardening and thickening of the skin and deeper tissues. The left leg is shorter because the disease has affected the growth of the bone and muscles."
• "We will treat the active disease with medications like methotrexate to stop it from progressing and prevent further shortening."
• "Physical therapy is very important to maintain joint flexibility and prevent contractures."
• "We will measure the leg length difference regularly. A shoe lift can help with the current discrepancy."
• "If the difference becomes significant, we may need to consult an orthopedic surgeon to discuss growth-modifying procedures."
• "With early and aggressive treatment, we can minimize long-term complications."

✅ Model Answer: • Mycophenolate mofetil (MMF) role:
- Second-line or steroid-sparing agent: Used for patients with refractory disease or intolerance to methotrexate.
- Mechanism: Inhibits inosine monophosphate dehydrogenase (IMPDH) → reduces lymphocyte proliferation.
- Dose: 600-1200 mg/m²/day (or 20-30 mg/kg/day) divided BID.
- Indications: Active linear scleroderma that is unresponsive to methotrexate; especially with deep tissue involvement or severe disease.
- Monitoring: CBC, liver function tests, renal function, and urinalysis (risk of leukopenia, infection).
- Evidence: Some studies show efficacy in pediatric localized scleroderma.

✅ Model Answer: • Prognosis: Highly variable, depends on the extent of deep tissue involvement and response to treatment.
- Disease course: Often follows a relapsing-remitting course; may become inactive after 3-5 years.
- Early aggressive treatment: Improves outcomes and reduces the risk of permanent deformity.
- Residual effects: Skin atrophy, hyperpigmentation, hypopigmentation, and limb-length discrepancy may persist.
- Functional outcomes: With physical therapy and orthopedic management, most children maintain good function.
- Recurrence: Rare after prolonged remission, but relapses can occur.
- No systemic involvement: Linear scleroderma does not progress to systemic sclerosis.